13062-61-8 Usage
Description
alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride, also known as 4-Hydroxy-3-methoxy Amphetamine, is a chemical compound that serves as a metabolite of 3,4-methylenedioxymethamphetamine (MDMA). It is characterized by its significantly lower potency compared to MDMA in inhibiting [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.
Uses
Used in Pharmaceutical Research:
alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride is used as a research compound for understanding the effects and mechanisms of action of MDMA and its metabolites. Its application in this field aids in the development of potential therapeutic strategies and interventions related to MDMA use and its consequences.
Used in Neurochemical Studies:
In the field of neurochemistry, alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride is used as a labelled analogue to study the transport and interaction of neurotransmitters such as noradrenaline and serotonin (5-HT) in mammalian cell lines. This helps researchers gain insights into the neurochemical processes affected by MDMA and its metabolites.
Used in Toxicology and Drug Metabolism:
alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride is utilized as a tool in toxicology and drug metabolism research to investigate the metabolic pathways and potential toxic effects of MDMA and its metabolites. This information is crucial for assessing the safety and potential risks associated with MDMA use.
Used in Drug Development:
In the pharmaceutical industry, alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride may be used as a starting point or reference compound in the development of new drugs with similar structures but potentially improved pharmacological properties, reduced side effects, or lower abuse potential.
Used in Forensic Analysis:
alpha-Methyl-beta-(3-methoxy-4-hydroxyphenyl)ethylamine hydrochloride is employed in forensic analysis as a marker for the detection and identification of MDMA and its metabolites in biological samples. This application is essential for criminal investigations and legal proceedings involving the use or distribution of MDMA.
Check Digit Verification of cas no
The CAS Registry Mumber 13062-61-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,0,6 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 13062-61:
(7*1)+(6*3)+(5*0)+(4*6)+(3*2)+(2*6)+(1*1)=68
68 % 10 = 8
So 13062-61-8 is a valid CAS Registry Number.
13062-61-8Relevant articles and documents
Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines
Montgomery,Buon,Eibauer,Guiry,Keenan,McBean
, p. 1121 - 1130 (2008/03/13)
Background and purpose: Illegal 'ecstasy' tablets frequently contain 3,4-methylenedioxymethamphetamine (MDMA)-like compounds of unknown pharmacological activity. Since monoamine transporters are one of the primary targets of MDMA action in the brain, a number of MDMA analogues have been tested for their ability to inhibit [3H]noradrenaline uptake into rat PC12 cells expressing the noradrenaline transporter (NET) and [3H]5-HT uptake into HEK293 cells stably transfected with the 5-HT transporter (SERT). Experimental approach: Concentration-response curves for the following compounds at both NET and SERT were determined under saturating substrate conditions: 4-hydroxy-3-methoxyamphetamine (HMA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH), 2,5-dimethoxy-4- bromophenylethylamine (2CB), 3,4-dimethoxymethamphetamine (DMMA), 3,4-methylenedioxyphenyl-2-butanamine (BDB), 3,4-methylenedioxyphenyl-N-methyl- 2-butanamine (MBDB) and 2,3-methylenedioxymethamphetamine (2,3-MDMA). Key results: 2,3-MDMA was significantly less potent than MDMA at SERT, but equipotent with MDMA at NET. 2CB and BDB were both significantly less potent than MDMA at NET, but equipotent with MDMA at SERT. MBDB, DMMA, MDOH and the MDMA metabolites HMA and HMMA, were all significantly less potent than MDMA at both NET and SERT. Conclusions and implications: This study provides an important insight into the structural requirements of MDMA analogue affinity at both NET and SERT. It is anticipated that these results will facilitate understanding of the likely pharmacological actions of structural analogues of MDMA.
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.